-
Published 8/12/2025
Maurer MS, Berk JL, Damy T, Sheikh FH, González-Costello J, Morbach C, Delgado D, Bondue A, Azevedo O, Poulsen SH, Jankowska EA, Yang L, Bender S, Eraly SA, Jay PY, Vest J, Fontana M. Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B. J Am Coll Cardiol. 2025 Aug 12; 86(6):459-475. PMID: 40769675.
-
Published 6/23/2025
Berk JL, Lairez O, Schwartzmann P, Bender S, White MT, Jay PY, Danese D, Witteles R. Benefits of Patisiran on Functional Capacity in ATTR Cardiac Amyloidosis: Post Hoc Analysis of APOLLO-B. JACC Adv. 2025 Aug; 4(8):101876. PMID: 40555140.
-
Published 3/31/2025
Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O, Witteles R. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2025 Aug; 18(8):e012112. PMID: 40160093.
-
Published 3/1/2025
Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 01; 82(3):228-236. PMID: 39804640.
-
Published 2/3/2025
Conceição I, Berk JL, Weiler M, Kowacs PA, Dasgupta NR, Khella S, Chao CC, Attarian S, Kwoh TJ, Jung SW, Chen J, Viney NJ, Yu RZ, Gertz M, Masri A, Cruz MW, Coelho T. Correction: Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2025 Feb 03; 272(2):182. PMID: 39899052.